{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:00:52Z","timestamp":1767999652509,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00277-008-0488-6","type":"journal-article","created":{"date-parts":[[2008,4,9]],"date-time":"2008-04-09T11:24:05Z","timestamp":1207740245000},"page":"727-734","source":"Crossref","is-referenced-by-count":13,"title":["Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients"],"prefix":"10.1007","volume":"87","author":[{"given":"Saar","family":"Gill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven W.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Cull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Joske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Marlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,10]]},"reference":[{"key":"488_CR1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/sj.leu.2400861","volume":"11","author":"CA Koller","year":"1997","unstructured":"Koller CA, Kantarjian HM, Thomas D, O\u2019Brien S, Rios MB, Kornblau S, Murphy S, Keating M (1997) The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic lymphoma. Leukemia 11:2039\u20132044","journal-title":"Leukemia"},{"key":"488_CR2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreef M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547\u2013561","journal-title":"J Clin Oncol"},{"key":"488_CR3","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ (2004) Long-term doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensiveregimen, in adult acute lymphoblastic leukemia. Cancer 101:2788\u20132801","journal-title":"Cancer"},{"key":"488_CR4","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","volume":"104","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, O\u2019Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarian H (2004) Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624\u20131630","journal-title":"Blood"},{"key":"488_CR5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","volume":"17","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H (1999) Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461\u20132470","journal-title":"J Clin Oncol"},{"key":"488_CR6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569\u20131580","journal-title":"Cancer"},{"key":"488_CR7","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R (1998) Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803\u20133809","journal-title":"J Clin Oncol"},{"key":"488_CR8","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez M, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013\u20137023","journal-title":"J Clin Oncol"},{"key":"488_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","volume":"86","author":"DS Ritchie","year":"2007","unstructured":"Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, Szer J, Prince HM (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 86:101\u2013105","journal-title":"Ann Hematol"},{"key":"488_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.10381","volume":"74","author":"M Shapiro","year":"2003","unstructured":"Shapiro M, Wasik MA, Junkins-Hopkins JM, Rook AH, Vittorio CC, Itakura H, Frankel MC, Georgala S, Schuster SJ (2003) Complete remission in advanced blastic NK-cell lymphoma\/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol 74:46\u201351 (S-Plus 2000 User\u2019s Guide, Data Analysis Products Division, MathSoft, Seattle, WA)","journal-title":"Am J Hematol"},{"key":"488_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.784","volume":"24","author":"C Keane","year":"2006","unstructured":"Keane C, Gibbs S, Seymour JF, Mills AK, Grimmett K, Van Kuilenberg R, Saal R, Gill D, Prince HM, Marlton P, Mollee P (2006) The hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilise peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilisation. Hematol Oncol 24:159\u2013163","journal-title":"Hematol Oncol"},{"key":"488_CR12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","volume":"21","author":"JO Armitage","year":"2003","unstructured":"Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients. J Clin Oncol 21:897\u2013906","journal-title":"J Clin Oncol"},{"key":"488_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith SM, Le Beau MM, Hou D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102:43\u201352","journal-title":"Blood"},{"key":"488_CR14","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","volume":"95","author":"J Pedersen-Bjergaard","year":"2000","unstructured":"Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273\u20133279","journal-title":"Blood"},{"key":"488_CR15","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","volume":"22","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Scheignitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective trial of the German low grade lymphoma study group. J Clin Oncol 22:4926\u20134933","journal-title":"J Clin Oncol"},{"key":"488_CR16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMe048336","volume":"352","author":"J Pedersen-Bjergaard","year":"2005","unstructured":"Pedersen-Bjergaard J (2005) Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 352:1591\u20131594","journal-title":"N Engl J Med"},{"key":"488_CR17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","volume":"18","author":"IN Micallef","year":"2000","unstructured":"Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA, Rohatiner AZ (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947\u2013955","journal-title":"J Clin Oncol"},{"key":"488_CR18","unstructured":"Cancer Council Victoria. Clinical trials reference information. Available from: http:\/\/www.cancervic.org.au\/trials\/details.asp?ContentID=nhl11 (accessed April 22, 2007)"},{"key":"488_CR19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1080\/10428190600632832","volume":"47","author":"SW Lane","year":"2006","unstructured":"Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN (2006) Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma 47:1813\u20131817","journal-title":"Leuk Lymphoma"},{"key":"488_CR20","volume-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 1st edn.","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 1st edn.. IARC, Lyon"},{"key":"488_CR21","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The statistical analysis of failure time data, 2nd edn.","author":"JD Kalbfleisch","year":"2002","unstructured":"Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data, 2nd edn.. Wiley, Hoboken, New Jersey"},{"key":"488_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343\u2013346","journal-title":"Control Clin Trials"},{"key":"488_CR23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","volume":"121","author":"K Chaiwatanatorn","year":"2003","unstructured":"Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F (2003) Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 121:913\u2013918","journal-title":"Br J Haematol"},{"key":"488_CR24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","volume":"47","author":"C Cattaneo","year":"2006","unstructured":"Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Corlenghi E, Ungari M, Ruggeri G, Rossi G (2006) Delayed-onset peripheral blood cytopenias after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 47:1013\u20131017","journal-title":"Leuk Lymphoma"},{"key":"488_CR25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-103-2-195","volume":"103","author":"J Pedersen-Bjergaard","year":"1985","unstructured":"Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding M, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin\u2019s lymphomas: comparison with results obtained in patients treated for Hodgkin\u2019s disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195\u2013200","journal-title":"Ann Intern Med"},{"key":"488_CR26","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/1097-0142(19821201)50:11<2285::AID-CNCR2820501111>3.0.CO;2-B","volume":"50","author":"GA Gomez","year":"1982","unstructured":"Gomez GA, Aggarwal KK, Han T (1982) Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin\u2019s lymphoma. Cancer 50:2285\u20132288","journal-title":"Cancer"},{"key":"488_CR27","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2006.06.0673","volume":"24","author":"M Kalaycio","year":"2006","unstructured":"Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B (2006) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604\u20133610","journal-title":"J Clin Oncol"},{"key":"488_CR28","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","volume":"17","author":"JW Friedberg","year":"1999","unstructured":"Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman A (1999) Outcome in patients with myelodysplasic syndrome after autologous marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:3128\u20133135","journal-title":"J Clin Oncol"},{"key":"488_CR29","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V78.11.2814.2814","volume":"78","author":"CA Linker","year":"1991","unstructured":"Linker CA, Levitt LJ, O\u2019Donnell M, Forman SJ, Ries CA (1991) Treatment of adult acute lymphoblastic leukaemia with intensive cyclical chemotherapy: a follow-up report. Blood 78:2814\u20132822","journal-title":"Blood"},{"key":"488_CR30","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","volume":"20","author":"C Linker","year":"2002","unstructured":"Linker C, Damon L, Ries C, Navarro W (2002) Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukaemia. J Clin Oncol 20:2464\u20132471","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0488-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0488-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0488-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:45:47Z","timestamp":1588553147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0488-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0488-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,10]]}}}